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Agents that enhance production of nitric oxide (NO) and cyclic guanosine
monophosphate (cGMP) ameliorate the progression of renal fibrosis. How-
ever, the molecular mechanism of this process is not fully understood. We
hypothesize that the antifibrotic effects of cGMP and cGMP-dependent
kinase I (cGKI) are mediated via regulation of the TGFb signalling path-
way, both via ERK and the Smad-dependent route. Kidney fibrosis was
induced by unilateral ureter obstruction (UUO) in wild-type and cGKI-
deficient (cGKI-KO) mice. The cGMP/cGKI signalling pathway was acti-
vated by application of the soluble guanylate cyclase (sGC) stimulator
BAY 41-8543 (BAY), beginning 1 day after UUO. After 7 days, the antifi-
brotic effects of BAY were analysed by measuring mRNA and protein
expression of characteristic fibrotic biomarkers. The effects of cGMP/
TGFb on cultured fibroblasts were also analysed in vitro. BAY application
influenced the activity of the extracellular matrix (ECM)-degrading matrix
metalloproteases (MMP2 and MMP9) and their inhibitor tissue inhibitors
of metalloproteinase-1, the secretion of cytokines (e.g. IL-6) and the
expression pattern of ECM proteins (e.g. collagen, fibronectin) and profi-
brotic mediators (e.g. connective tissue growth factors and plasminogen-
activator inhibitor-1). Activation of the cGMP/cGKI signalling pathway
showed protective effects against fibrosis which were mediated by inhibi-
tion of P-Erk1/2 and translocation of P-smad3. The elucidation of these
signalling mechanisms might support the development of new therapeutic
options regarding cGMP/cGKI-mediated antifibrotic actions.
Fibrosis is characterized by excessive expression of
extracellular matrix (ECM). Fibrogenic factors promote
the fibrotic process such as transforming growth factors
(TGFb), plasminogen-activator inhibitor-1 (PAI-1) or
connective tissue growth factors (CTGF) [1]. TGFb is
involved in the differentiation of fibroblasts to myofi-
broblasts, which are characterized by the expression of
a-smooth muscle actin (aSMA). Myofibroblasts synthe-
size ECM proteins including collagen and fibronectin,
and they secrete cytokines, for example, IL-6.
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In addition, synthesis and degradation of ECM pro-
teins are determined by metalloproteinases (MMPs)
and tissue inhibitors of metalloproteinases (TIMPs).
Their expression pattern is regulated by MAPK/Erk
kinase, which promotes the progression of fibrosis
[2,3].
We evaluated the effects of the soluble guanylate
cyclase (sGC) stimulator BAY 41-8543 (BAY) on the
fibrotic kidney. Under physiological conditions, sGC
can be activated by nitric oxide (NO). Activated sGC
synthesizes the second messenger cyclic guanosine
monophosphate (cGMP) which then stimulates
cGMP-dependent protein kinases (cGK) [4]. We have
previously reported that cGMP suppresses renal fibro-
sis in particular via cGKIa, an isoform of cGK.
cGKIa is expressed in fibroblasts and myofibroblasts,
which are excessively produced after unilateral ureter
obstruction (UUO) [5]. Protective effects of sGC stim-
ulation on renal fibrosis in rats have already been
shown [6,7]. Thereby, BAY reduced apoptosis and
macrophage infiltration after relief of UUO [7], and
Sharkovska et al. [6] reported that sGC stimulation
improved creatinine clearance in hypertensive renin-
transgenic rats. However, the molecular mechanism by
which cGMP via cGKI affects the development of kid-
ney fibrosis has not yet been fully elucidated. There-
fore, we analysed the impact of BAY on fibrosis in a
mouse model of UUO using cGKI-knockout (cGKI-
KO)-mice. The present study investigates the functional
role of sGC stimulation in the fibrotic process, the sig-
nalling pathway as well as the underlying mechanisms
involved.
Results
Effect of BAY and function of cGKI on the mRNA
expression of different fibrotic biomarkers
As marker for fibrosis induction, we examined the
mRNA levels of aSMA, fibronectin, collagen1a1
(Col1a1), CTGF, TIMP-1, PAI-1, MMP2 and MMP9
(Fig. 1). One week after UUO surgery, the mRNA
levels were elevated in comparison to the contralateral
control kidney. Especially, aSMA (Fig. 1A), Col1a1
(Fig. 1C), TIMP-1 (Fig. 1E), PAI-1 (Fig. 1F) and
MMP2 (Fig. 1G) were strongly increased by UUO. In
contrast, the mRNA expression of fibronectin
(Fig. 1B) and CTGF (Fig. 1D) were only moderately
upregulated, and MMP9 (Fig. 1H) was nearly
unchanged.
To examine the role of NO/cGMP signalling in
renal fibrosis, we injected the sGC stimulator BAY. A
significant raise of cGMP in kidney tissues of BAY-
treated mice in comparison to untreated mice indicat-
ing a BAY-induced stimulation of sGC was measured
(Fig. S1). BAY treatment decreased the mRNA
Fig. 1. Effect of BAY in wt- and cGKI-KO-kidneys on the mRNA expression levels of (A) aSMA, (B) fibronectin, (C) Col1a1, (D) CTGF, (E)
TIMP-1, (F) PAI-1, (G) MMP2 and (H) MMP9. In wt-mice, BAY caused a significant decrease in the mRNA expression of (A) aSMA, (B)
fibronectin, (C) Col1a1, (D) CTGF, (E) TIMP-1, (G) MMP2 and (H) MMP9 with the exception of (F) PAI-1. In cGKI-KO-mice sGC stimulation
showed no significant decrease in the mRNA levels (A–H). The results are shown as the x-fold change in mRNA expression in the fibrotic
kidney relating to the opposite healthy kidneys whose mRNA expression was set to one. In each mouse strain the untreated mice were
compared with BAY-treated mice. Significant differences between two groups are indicated with asterisks (*P < 0.05, **P < 0.01). The
columns show the number of animals which were used. The right columns illustrate the data of GKI-KO-mice and patterned columns the
data of BAY-treated mice.
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expression of all investigated biomarkers of fibrosis
with the exception of PAI-1 (Fig. 1F). The expression
of PAI-1 was reduced but the difference did not reach
significance. To explore whether cGKI is involved in
the impact on the fibrotic process, we analysed cGKI-
KO-mice. As previously reported, untreated cGKI-
KO-mice showed less mRNA expression than
untreated wild-type (wt) mice [5]. However, the
mRNA expression of cGKI-KO-mice was not influ-
enced by BAY application (Fig. 1).
Effect of BAY and role of cGKI on the protein
expression of: aSMA, fibronectin, Col1a1 and
total collagen
After UUO, the interstitial accumulation of protein
expression of aSMA, fibronectin and Col1a1 was
increased in wt- and cGKI-KO kidneys as demon-
strated by immunofluorescence analysis (Fig. 2A–C).
The quantitative analysis revealed that BAY signifi-
cantly reduced the protein expression of aSMA, fibro-
nectin and Col1a1 in wt-, but not in cGKI-KO-
kidneys (Fig. 2A–C). The same pattern was present
when we used the Sirius red/fast green staining for
total collagen. In wt-, but not in cGKI-KO-kidneys,
sGC stimulation by BAY significantly downregulated
the level of total collagen (Fig. 2D).
Effect of BAY and function of cGKI on the activity
or protein expression of TGFb target genes
As expected, UUO increased the protein expression of
the TGFb target gene CTGF in comparison to the
healthy kidney (Fig. 3A). The quantitative analysis,
which compared only fibrotic kidneys, confirmed that
the protein expression of CTGF was significantly
diminished by BAY in fibrotic wt-kidneys. However,
treatment of cGKI-KO-mice did not result in a reduc-
tion of CTGF (Fig. 3A). Figure 3B demonstrates that
PAI-1-expression was not significantly influenced by
BAY. The protein expression of TIMP-1 was not
changed by UUO in comparison to the contralateral
healthy kidney (Fig. 3C). Intriguingly, TIMP-1 was
significantly higher in BAY treated than in untreated
fibrotic wt-mice. In cGKI-KO-mice, we detected no
increase in TIMP-1 expression following BAY admin-
istration (Fig. 3C). The latent and active forms of
MMP2 and the latent forms of MMP9 were elevated,
but the active forms of MMP9 were reduced by UUO
(data not shown). In agreement with the increase in
TIMP-1, which is an inhibitor of MMPs, the latent
and active forms of MMP2 (Fig. 4A,B) and the latent
forms of MMP9 (Fig. 4A,C) were significantly dimin-
ished by BAY. This was again only observed in wt-,
but not in cGKI-KO-kidneys.
Effect of cGMP/cGKI on the TGFb signalling
pathway
At first we analysed the influence of cGMP/cGKI on
the TGFb/smad signalling pathway. Isolated fibroblasts
of wt- (left side of Fig. 5A) and cGKI-KO-kidneys
(right side of Fig. 5A) were pretreated with cGMP or
vehicle followed by exposure to TGFb or vehicle
(Fig. 5A). We quantified the intranuclear and extranu-
clear fluorescence intensity of P-smad3 respectively. Fig-
ure 5B shows that TGFb treatment significantly
enhanced nuclear fluorescence intensity of P-smad3 but
pretreatment with cGMP significantly limits nuclear
translocation of P-smad3 in fibroblasts of wt-kidneys in
the presence of TGFb. cGMP alone had no effects (data
not shown). Intriguingly in fibroblasts of cGKI-KO-kid-
neys pretreatment with cGMP did not change the
translocation of P-smad3 (Fig. 5C). In contrast to P-
smad3, P-smad2 was not influenced by preincubation
with cGMP (data not shown). Isolated fibroblasts
expressed sGC but during culturing the expression of
sGC was downregulated (data not shown). Therefore,
we stimulated the cells only with cGMP and not with
the sGC stimulator BAY. Furthermore, we quantified
the total cellular fluorescence intensity of P-smad3
which was significantly increased by TGFb treatment
but interestingly not significantly changed by cGMP
pretreatment (Fig. S2). In pulmonary artery smooth
muscle cells activation of cGMP/PKG limited TGFb-
induced nuclear translocation of smad3 by sequestering
smad3 with cytosolic b2-tubulin [8]. Therefore, we per-
formed a coimmunoprecipitation (Co-IP) of stimulated
Fig. 2. Effect of BAY in wt- and cGKI-KO-kidneys on the protein levels of (A) aSMA, (B) fibronectin, (C) Col1a1 and (D) total Collagen.
Metamorph offline was used for the quantification of fluorescence-intensity of (A) aSMA, (B) fibronectin and (C) Col1a1.
Immunofluorescence staining of (A) aSMA (Alexa488, shown in red), (B) fibronectin (Alexa647, shown in red) and (C) Col1a1 (Alexa647,
shown in red) in healthy, UUO-untreated and UUO-BAY-treated kidneys of wt- and cGKI-KO-mice. Total collagen levels in the kidneys were
measured by Sirius red/fast green staining (D). The protein expression of (A) aSMA, (B) fibronectin, (C) Col1a1 and (D) total Collagen was
significantly diminished in wt-mice, but not in cGKI-KO-mice by BAY. Thereby, the increase in protein by UUO was related to the healthy
kidney. In each mouse strain the untreated mice were compared with BAY-treated mice. Significant differences between two groups are
indicated with asterisks (*P < 0.05, **P < 0.01). The columns show the number of animals which were used. The right columns illustrate
the data of GKI-KO-mice and patterned columns the data of BAY-treated mice.
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fibroblasts to check whether smad3 and b2-tubulin form
a cGMP-dependent complex. Figure 5D shows that b2-
tubulin antibody precipitated cGKIa, P-smad3 and
smad3 in TGFb- and cGMP/TGFb-stimulated fibrob-
lasts. However, in contrast to Gong et al. [8], there was
no increase in the intensity of the bands after pretreat-
ment with cGMP.
Second, the phosphorylation of Erk1 and Erk2 (P-
Erk1/2) was assessed. UUO increased the
phosphorylation and the protein expression of Erk1
and Erk2 (Fig. 6A). Immunoblots with antibodies
against total Erk1 and Erk2 demonstrated that their
expression is increased by UUO, but not changed by
Bay administration (Fig. 6A). Accordingly, in Fig. 6B,
C only fibrotic kidneys are compared and P-Erk1/2 is
normalized to Erk1/2 and related to untreated fibrotic
wt-kidneys. sGC stimulation caused a significant
decrease in P-Erk1 and P-Erk2 in fibrotic kidneys of
Fig. 3. Effect of BAY in wt- and cGKI-KO-kidneys on the protein levels of (A) CTGF, (B) PAI-1 and (C) TIMP-1. The immunoblots show the
protein expression of CTGF (A), PAI-1 (B) and TIMP-1 (C) in wt-mice of healthy and fibrotic kidneys (BAY treated or untreated). The graphs
statistically compare the protein expression of CTGF (A), PAI-1 (B) and TIMP-1 (C) in fibrotic wt- and cGKI-KO-kidneys. CTGF (A) and TIMP-1
(C) are significantly influenced by BAY in wt-, but not in cGKI-KO-kidneys. Thereby, each value of the used markers of wt- and cGKI-KO-
kidneys is related to the mean value of untreated fibrotic wt-kidneys which was set to one and normalized to the corresponding GAPDH.
The protein expression of GAPDH was changed by UUO but not by BAY. Therefore, the statistic compares only fibrotic kindeys. Significant
differences between two groups are indicated with asterisks (*P < 0.05). The columns show the number of animals which were used. The
right columns illustrate the data of GKI-KO-mice and patterned columns the data of BAY-treated mice.
Fig. 4. Effect of BAY in fibrotic wt- and cGKI-KO-kidneys on the activity of MMP2 and MMP9. Latent and active MMP2 and MMP9 of
fibrotic wt- and cGKI-KO-kidneys were determined by Gelatin zymography assays (A). In fibrotic wt-kidneys, latent and active MMP2 (B) and
latent MMP9 (C) were significantly reduced after BAY application. In cGKI-KO-kidneys BAY showed no effects regarding the activity of
MMP2 and 9. Each value of wt- and cGKI-KO-kidneys is related to the mean value of untreated fibrotic wt-kidneys which was set to one.
Significant differences between two groups are indicated with asterisks (*P < 0.05, **P < 0.01). The columns show the number of animals
which were used. The right columns illustrate the data of GKI-KO-mice and patterned columns the data of BAY-treated mice.
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treated in contrast to untreated wt-mice. This BAY-
induced decrease of Erk1/2 phosphorylation in fibrotic
wt-kidneys was not due to changed protein expression
of Erk1/2. In cGKI-KO-kidneys, the Erk phosphoryla-
tion was not reduced by BAY (Fig. 6B,C).
Increased IL-6 levels in cGKI-KO-mice
It has been shown that IL-6 promotes fibrosis [9].
UUO significantly increased the IL-6 concentration in
serum of wt-mice. Administration of BAY tends to
result in diminished IL-6 levels in serum of wt-mice
compared with untreated wt-mice. Interestingly, the
IL-6 concentration was significantly higher in
untreated and treated cGKI-KO-mice and fluctuated
much more than in wt-mice (Fig. 7).
Effect of BAY and role of cGKI on the renal
function examining serum creatinine
The serum level of creatinine increased significantly
after 7 days of UUO. Following BAY administration,
serum creatinine was decreased, but there was no
significant difference between BAY treated and
untreated wt-mice. Conversely, in cGKI-KO-mice,
BAY influenced in no way the serum creatinine
(Fig. 8).
Discussion
In the present study, we have investigated the func-
tional role of sGC stimulation in regulating renal
fibrosis. BAY reduced the mRNA- and protein
Fig. 5. Effect of cGMP on the TGFb/smad signalling pathway in renal wt- and cGKI-KO-fibroblasts. Serum-starved fibroblasts which were
isolated from wt- (left sided) and cGKI-KO-kidneys (right sided) were pretreated with 8Br-cGMP (1 mM) or vehicle (control) for 1 h, followed
by TGFb (2 ngmL1) or vehicle for 1 h and stained with P-smad3 (Alexa647 anti-rabbit, shown in red) and DAPI (shown in blue) (A). The
statistic of the fluorescence intensity of P-smad3 in nucleus or cytosol is demonstrated in (B) wt-fibroblasts and (C) cGKI-KO-fibroblasts. Wt-
fibroblasts were stimulated with TGFb or cGMP/TGFb for the coimmunprecipitation (Co-IP) analysis which was performed with whole cell
extracts using anti-b2-tubulin antibody. The blot was probed with anti-cGKIa and smad3, then after stripping with anti-P-smad3 and then
after stripping with anti-b2-tubulin (D). Significant differences between two groups are indicated with asterisks (*P < 0.05, ***P < 0.001).
The experiments were repeated five to seven times.
Fig. 6. Effect of BAY on the TGFb/Erk signalling pathway in wt- and cGKI-KO-mice (A) Representative western blots of Erk1/2 in healthy/
fibrotic kidney tissue of wt-mice untreated/treated with BAY. The graphs statistically compare the protein expression of P-Erk1 (B) and P-
Erk2 (C) in fibrotic wt- and cGKI-KO-kidneys. P-Erk1 (B) and P-Erk2 (C) were significantly reduced by BAY in wt-, but not in cGKI-KO-kidneys.
Thereby, each value of P-Erk1/2 of wt- and cGKI-KO-kidneys is related to the mean value of untreated fibrotic wt-kidneys which was set to
one and normalized to the corresponding Erk1/2. Significant differences between two groups are indicated with asterisks (*P < 0.05). The
columns show the number of animals which were used. The right columns illustrate the data of GKI-KO mice and patterned columns the
data of BAY-treated mice.
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expression of different fibrosis marker. The antifibrotic
impact of sGC stimulation was not observed in cGKI-
KO-mice, suggesting that cGKI mediates the repair
process of renal fibrosis.
Our study confirmed that the serum creatinine,
which is a parameter for renal function, is increased
after UUO [10]. However, it was not significantly
reduced by BAY in wt-mice and unchanged in cGKI-
KO-mice. Our results are in line with the nephropro-
tective effects of PDE5 inhibitors which also enhance
the cGMP pool [11–13]. cGKI-KO-mice have higher
IL-6 levels [14,15] which exert profibrotic effects [9,16].
Conforming with our present study, the IL-6 levels
were increased by UUO and treated, as well as
untreated cGKI-KO-mice showed a higher IL-6 con-
centration than wt-mice. However, cGKI-KO-kidneys
revealed no more pronounced fibrosis compared to wt-
kidneys suggesting that other signalling pathways as
IL-6 are important for induction of renal fibrosis. The
application of BAY reduced the IL-6 concentration,
but the difference was not significant. Considering the
effects of the MAPK signalling, the phosphorylation
of Erk promotes fibrosis [17]. In cardiac fibrosis the
inhibition of Erk phosphorylation by cGMP has
already been discussed [18]. Our results confirmed the
decrease in phosphorylation of Erk after BAY applica-
tion. Consistent with our data, Beyer et al. [19] have
also identified that the stimulation of sGC decreased
TGFb signalling through the inhibition of Erk1/2
phosphorylation. Additionally, we observed that
cGMP influenced via cGKI the phosphorylation of
Erk because in cGKI-KO-mice, the effects of BAY
were lower.
It is generally accepted that TGFb acts by stimula-
tion of its downstream mediator smad2 and smad3.
Latest studies report that diminished smad2- as well
as smad3 phosphorylation results in enhanced renal
fibrosis [20–22]. However, it is also recently discussed
that phosphorylation of smad2 and smad3 by TGFb
exerts reverse effects in renal fibrosis. Smad2 maybe
plays a protective role negatively regulating the
smad3 signalling. TGFb activates smad2 which
diminishes TGFb1/smad3 signalling, including phos-
phorylation, nuclear translocation and the binding of
smad3 to the Col1 promoter, leading to augmented
collagen synthesis [23,24]. In our study, phosphory-
lated smad2 was unaffected by cGMP in renal fibrob-
lasts (data not shown). However, nuclear
translocation of P-smad3 was diminished by cGMP
in the presence of TGFb in wt-, but not in cGKI-
KO-fibroblasts. Interestingly cGMP inhibited only the
translocation of P-smad3, but not the phosphoryla-
tion of smad3 (Fig. S2). In contrast to our study,
Beyer et al. [19] showed that nuclear P-smad2- and
P-smad3 levels and smad reporter activity were unaf-
fected by sGC stimulation in human fibroblasts. As
already mentioned in pulmonary artery smooth
Fig. 7. Effect of BAY on the IL-6 levels in the serum of wt- and
cGKI-KO-mice. The IL-6 levels in serum of both treated and
untreated cGKI-KO-mice were significantly higher than in
corresponding wt-mice. However, BAY itself revealed no
significant effects in wt- and in cGKI-KO-mice. Significant
differences between two groups are indicated with asterisks
(**P < 0.01, ***P < 0.001). The columns show the number of
animals which were used. The right columns illustrate the data of
GKI-KO mice and patterned columns the data of BAY-treated mice.
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Fig. 8. Effect of BAY on serum creatinine in wt- and cGKI-KO-
mice. UUO significantly increased creatinine in the serum of wt-
and cGKI-KO-mice. BAY did not significantly influence creatinine in
wt-mice. Significant differences between two groups are indicated
with asterisks (*P < 0.05, **P < 0.01). The columns show the
number of animals which were used. The right columns illustrate
the data of GKI-KO-mice and patterned columns the data of BAY-
treated mice.
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muscle cells, activation of cGMP/PKG limited
TGFb-induced nuclear translocation of smad3 by
sequestering smad3 with cytosolic b2-tubulin [8].
However, in contrast we did not detect an increase in
P-smad3–b2-tubulin interaction after pretreatment
with cGMP. In our study exists a cGKIa–P-smad3–
b2-tubulin interaction in fibroblasts, but the intensity
of this interaction is not influenced by cGMP. Conse-
quently, the observed inhibition by cGMP of TGFb-
induced nuclear translocation of P-smad3 cannot be
explained by sequestering P-smad3 with cytosolic b2-
tubulin. CTGF is downstream of TGFb signalling
and upregulated in response to TGFb stimulation
[25]. However, the regulation of CTGF expression via
cGMP is controversially discussed. Hewitson et al.
and Beyer et al. showed that cGMP is not able to
decrease the CTGF expression in fibroblasts, [1,19]
which contrasts our study illustrating reduced CTGF
expression with BAY.
Expression of PAI-1, which acts profibrotic, is
slightly attenuated by BAY. TGFb1 activates PAI-1
and PAI-1, in turn, stimulates TGFb1 [26]. The
expression of PAI-1 is regulated via TGFb1-induced
Erk phosphorylation [27] which is significantly reduced
by BAY.
After UUO, the MMP2 mRNA is adjusted much
higher than MMP9. Therefore, MMP2 appears to be
more crucial in the development of renal fibrosis than
MMP9. Of importance is the fact that BAY-induced
increase in TIMP-1 expression was accompanied by
diminished MMP2 activity. TIMPs do not reveal a
high specificity for any particular MMP [28], but we
suppose that the diminished activity of MMP2 by
BAY maybe caused by the regulation of substantial
increased TIMP-1. The role of MMPs in developing
renal fibrosis is very complex and subsequently differ-
ently discussed. On the one hand, MMP exert antifi-
brotic effects degrading diverse components of the
ECM. On the other hand, they are implicated in
pathological processes such as fibrosis and thereby
degrading basal membrane. Especially, MMP2
degrades collagen IV, which is an essential part of the
basal membrane [29]. A TGFb-induced increase of the
MMP2 protein and mRNA is also reported [30]. In
turn, enhanced MMP activity can stimulate the TGFb-
complex, which afterwards activates fibroblasts and
provokes the synthesis of collagen [31]. Accordingly,
the BAY-induced reduction of MMP activity may lead
to reduced TGFb activity, which correlates with the
observed decreased expression of TGFb target genes.
Considering this, the decrease in MMP2 activity by
cGMP/cGKI can ameliorate the progression of renal
fibrosis.
BAY application in rats was previously shown to
ameliorate renal injury after relief of ureteral obstruc-
tion [32]. In the clinics, renal damage depends on the
duration until relief of ureteral obstruction [33]. It has
to be evaluated clinically in the future whether applica-
tion of sGC stimulators might be a therapeutical
approach to diminish renal fibrosis upon ureteral
obstruction and to enhance renal recovery after relief.
Conclusion
The results of the present study suggest a therapeutic
potential of BAY application in renal fibrosis. The
antifibrotic effect of BAY is mediated via cGMP/cGKI
by inhibition of Erk and smad3 signalling pathways
(Fig. 9).
Materials and methods
Mice
129/Sv-WT and 129/Sv-cGKI-KO-mice [34] were bred and
maintained in the animal facilities of the University of
Regensburg.
The investigation conforms to the guide for the Care and
Use of Laboratory Animals published by the US National
Fig. 9. Proposed model demonstrating a possible mechanism for
BAY to intervene in the TGFb signalling pathway in renal fibrosis.
Stimulation of sGC by BAY can activate cGKI, which can restrict
TGFb signalling by inhibition of a smad-dependent pathway to
augment target gene transcription, or a smad-independent pathway
which is mediated via Erk1/2. GTP, guanosine triphosphate.
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Institute of Health. The experimental protocols were
approved by the local authorities for animal research
(Regierung der Oberpfalz, Bayern, Germany; #54-2532.1-
02/10) and were conducted according to the German law
for animal care.
Unilateral ureter obstruction
The renal fibrosis was induced by UUO in 6–12-week-old
mice as described in [5]. The application with BAY 41-8543
(BAY; daily, intraperitoneal, 4 mgkg bw1) started 24 h
after surgery using water, glycerol, PEG400 as vehicle.
After 7 days, the fibrotic process was analysed.
Quantitative RT-PCR
Real-time PCR of aSMA, fibronectin, Col1a1, CTGF,
PAI-1, TIMP-1, MMP2, and MMP9 was performed as pre-
viously described [5]. 18S rRNA served as housekeeper
gene. The results are shown as the x-fold change in mRNA
expression (2DDCt ) in the fibrotic kidney relating to the
opposite healthy kidneys whose mRNA expression was set
to one.
Sirius red/fast green
Collagen levels were determined by Sirius red/fast green
method [5]. We calculated the increase (%) of collagen (col-
lagen/nonprotein collagen) after 7 days UUO related to the
healthy kidney.
Immunofluorescence
The fixation, staining and quantification of kidney tissues
were performed as previously reported [5]. The quantifica-
tion of aSMA, fibronectin, Col1a1 and total collagen was
related to the contralateral healthy kidney. The fluorescence
intensity was quantified using the metamorphic offline soft-
ware (Visitron Systems, Puchheim, Germany).
Western blot analysis
The protein expression of CTGF, PAI-1 (Santa Cruz
Biotechnology, Heidelberg, Germany), Erk1/2, P-Erk1/2
(Cell Signaling, Danvers, MA, USA) and TIMP-1 (Sigma
Aldrich, Taufkirchen, Germany) was assayed by western
blotting [5]. Representative immunoblots show the influence
of UUO in comparison to the contralateral healthy kidney
and the effects of BAY in healthy and fibrotic wt-kidneys.
The graphs statistically compare exclusive fibrotic kidneys.
The values of all markers of the fibrotic wt- and cGKI-KO-
kidneys were related to the mean values of fibrotic untreated
wt-kidneys. This ratio was set to one and normalized to the
corresponding glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Cell Signaling) respectively to Erk1/2 for P-Erk1/
2 values. For quantification, ImageJ densitometry was used
(BioRad, M€unchen, Germany).
Gelatin zymography assay
The activity of MMP2 and MMP9 was detected using gela-
tin zymography, which can distinguish between latent and
active forms of proteinases.
Briefly, the culture medium was electrophoresed in a SDS/
PAGE gel containing 0.1% gelatin. The gel was loaded with
70 lg/35 lg total protein for MMP2/MMP9. The gel was
washed (100 mM NaCl and 2.5% Triton X-100 in 50 mM
Tris-HCl, pH 7.5) to remove SDS and incubated in a reaction
buffer (200 mM NaCl, 0.02% NaN3, 0.5 lM ZnCl2, 1 mM
CaCl2, 2% Triton X-100, in 50 mM Tris-HCl, pH 7.5) for
enzymatic reaction at 37 °C overnight. Finally, the gel was
stained with Coomassie blue, and destained in 10% acetic
acid/30% methanol and quantified using IMAGEJ software
(open source). MMPs in fibrotic tissue were expressed as rela-
tive values of markers in kidneys from untreated wt-mice.
Cell culture
The fibroblasts of wt- and cGKI-KO-mice were isolated and
stained as described previously [5]. The cells were pretreated
with 8Br-cGMP (Biolog, Bremen, Germany; 1 mM, 1 h,
37 °C) or vehicle followed by exposure to TGFb (Biomol,
Hamburg, Germany; 2 ngmL1, 1 h, 37 °C) or vehicle.
Nuclei were stained with DAPI (gift from Armin Kurtz,
University Regensburg). P-smad3 and P-smad2 (Cell Sig-
nalling), respectively, were detected using an Alexa647-con-
jugated anti-rabbit secondary-antibody (1 : 200; Invitrogen,
Karlsruhe, Germany) for 2 h at room temperature. Cover-
slips were washed, mounted with glycerol and analysed using
an Axiovert 200 microscope (Zeiss, Jena, Germany). To
ensure a valid comparison, images were randomly selected
from different fields. The intranuclear and extranuclear fluo-
rescence-intensity of three to six equal areas was measured
respectively. Then, the mean value of intranuclear and
extranuclear fluorescence intensity of P-smad3 was deter-
mined respectively. For the quantification of the fluorescence
intensity all values were related to values of untreated wt-
fibroblasts (control) using the metamorphic offline software.
(Co-)immunoprecipitation
The stimulated (TGFb/cGMP+TGFb) cells were lysed in
2% Lubrol-PX buffer [20 mM Tris; 150 mM NaCl, 2%
Lubrol (nonaethylenglycol-monododecylether)] containing
phosphatase inhibitors (Roche, Mannheim, Germany) and
protease inhibitors. After homogenization and centrifuga-
tion (18 000 g, 10 min, 4 °C) the protein concentration of
the supernatant was determined by a Lowry-based method.
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The reactions were completed with Co-IP buffer (50 mM
Tris-HCl, pH 7.5, 15 mM EGTA, 100 mM NaCl, 0.1% Tri-
ton X-100) containing also phosphatase inhibitors (Roche)
and protease inhibitors.
About 1000–1500 lg of cell lysates was given onto the
beads. Two microgram b2-tubulin-antibody (Sigma Aldrich)
was added and incubated on ice 90 min. Meanwhile 40 lL of
protein-A-G-Sepharose beads (Thermo Scientific, Dreieich,
Germany) were pretreated for each immunoprecipitation.
They were washed three times with Co-IP buffer, then
blocked with 3% BSA in Co-IP buffer and washed three
times at least once more. After that, the incubated cell lysates
were centrifugated (18 000 g, 10 min, 4 °C), then the super-
natant was added to the washed and blocked Sepharose
beads and rotated overnight at 4 °C. Following this, three
washing steps were performed (100 g, 4 °C, 1 min) and the
precipitate was eluted with Laemmli buffer 29. Proteins were
separated by SDS/PAGE (12.5%) and blotted to polyvinyli-
dene difluoride membrane (Merck Millipore, Darmstadt,
Germany). The blots were incubated with anti-smad3, anti-
P-smad3 (Cell Signalling), anti-cGKIa [35] and anti-b2-tubu-
lin, at 4 °C overnight. Bands were visualized by use of an
ECL select Western Blotting Detection Reagent (GE Health-
care, Amersham, UK). Coimmunprecipitation of cell
extracts without antibody and Co-IP buffer with antibody,
respectively, were used as controls for the specifity of the Co-
IP analysis (data not shown).
Determination of IL-6 and cGMP
For measurement of IL-6 levels in serum, blood was drawn
in anaesthetized (2% isoflurane) mice from the retrobulbar
plexus and centrifugated (8 min, 1000 g). Afterwards, the
IL-6 levels in the serum were determined with mouse IL-6
Quantikine ELISA Kit, (R&D Systems, Wiesbaden-Nor-
denstadt, Germany). For determination of cGMP concen-
tration in tissue, the kidneys were removed and assessed
with cGMP-EIA kit (IBL, Cayman, UK).
Serum creatinine
Serum creatinine was determined by HPLC as previously
reported with minor modifications [5]. In brief, 10 lL
serum was mixed with 50 lL perchloric acid to precipitate
proteins. The tube was vortexed and kept at 4 °C for
15 min. Following centrifugation (5 min, 10 000 g), an ali-
quot of 5 lL of the supernatant was injected into the
HPLC apparatus (Prominence LC20 series equipped with a
LC20A photometric detector set at 234 nm; Shimadzu,
Duisburg, Germany). Separation was performed using a
Zorbax 300-SCX 5 lm, 150 9 4.6 mm, analytical column
(Agilent, Waldbronn, Germany) and a mobile phase con-
sisting of 5 mM sodium acetate (pH = 5.1)/acetonitrile
[800 : 200 (v : v)]. Creatinine eluted after 6.3–6.5 min at a
flow rate of 1.0 mLmin1 (column temperature 35 °C).
Statistical analysis
All data are expressed as mean  SEM. For calculation of
statistical differences between two means, the unpaired Stu-
dent’s t-test (two-tailed, confidence interval 95%) was used.
If the difference between two groups was statistically signif-
icant, then it is indicated by asterisks (*P < 0.05;
**P < 0.01; ***P < 0.001). n indicates the number of
animals.
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